1946
|
Foundation of Biotest Serum-Institut GmbH by Carl Adolf Schleussner and Dr Hans Schleussner; initial focus on research on blood typing serology
|
1948
|
The test serum anti-D for the determination of the rhesus factor is introduced world-wide as one of the first products of this kind
|
1949
|
Production of the first plasma protein product, Biseko® |
1961
|
Ground breaking for the new production facilities at Dreieich followed by gradual transfer of all activities from Frankfurt to Dreieich
|
1968
|
Foundation of first European distribution subsidiaries in Italy and Austria
|
1971
|
Production of the first polyspecific immunoglobulin preparation
|
|
1973
|
Foundation of distribution subsidiary in U.K. |
1979
|
Development of the first air sampler as the start of Biotest's Microbiological Diagnostic business (hygiene monitoring)
|
1982 and 1983
|
Market introduction of the hyper-immunoglobulin preparations Hepatect®, Cytotect®, and Varitect®
|
|
1985
|
- Market introduction of the first intravenously tolerable IgM-enriched immunoglobulin Pentaglobin®
- Foundation of distribution subsidiary in Switzerland
|
|
1986
|
Reorganization of Biotest Serum-Institut GmbH to Biotest AG, advancing the expansion of the business divisions Pharmaceuticals and Diagnostics |
|
1987
|
As a world-wide operating corporation, Biotest goes public on the Frankfurt Stock Exchange |
| 1988 |
Foundation of distribution subsidiary in Hungary
|
|
1993
|
Production of the first double virus-inactivated factor VIII preparation (Haemoctin®) for haemophiliacs |
| 2001 |
Foundation of the German plasma collection company Plasma Service Europe GmbH
|
|
2004
|
- Start of operation of the extensively modernised pharmaceutical production facility, followed by further additions to capacity (total investments over € 80 million)
- Market introduction of Intratect®
|
|
2005
|
Approval of the fully-automated blood typing system TANGO and the corresponding reagents for the US market |
|
2007
|
Purchase of plasma protein business of Nabi Biopharmaceuticals Corp.
|
|
2008
|
- Foundation of the Hungarian plasma collection company Plazmaszolgálat Kft.
- FDA authorises marketing of manual reagents for blood group typing
- European approval for Haemonine® (Factor IX)
|
|
2010
|
- Expansion of immunoglobulin production capacity at the Dreieich site from 2 to 4 tons
- Marketing authorization for Zutectra®
- Sale of Medical Diagnostics business to Bio-Rad completed
- Foundation of distribution subsidiary in Spain
|
| 2011 |
- Cooperation contract on co-development and co-marketing of monoclonal antibody BT-061 with Abbott Laboratories, Inc.
- Sale of microbiological monitoring business to Merck KGaA
- Foundation of distribution subsidiary in Brazil
|
2012
|
- Europe-wide marketing authorisation of Intratect® 100 g/l (10%)
- Marketing authorization Bivigam® in the US
|
|
2013
|
- Market launch of Bivigam® in the US
- New share issuance successfully secures € 76 million capital increase
- Biotest support "project recovery" for the production of haemophilia preparations for developing countries
- Private debt placement rises € 210 million
- Market authorization of Albiomin® in Brazil, commissioning of the extended Albiomin® production capacity
- Start of the expansion project "Biotest Next Level" at the Dreieich site in Germany
|
| 2014 |
- Marketing authorisation Albiomin in China
- Foundation of distribution subsidiary in France
|
| 2015 |
- Biotest share split with a ratio 1:3
- Opening of day care centre BioNest
- Start of clinical phase IIa trial with the monoclonal antibody BT-063 in the indication Systemic Lupus Erythematosus (SLE)
- Commissioning of new Plasma goods receipt area including virological test laboratories
|
| 2016 |
- Biotest opens six plasma collection centres
- Cooperation agreement with Octapharma for German-speaking markets to offer a recombinant factor VIII preparation
- Start of global clinical phase III study of IgG Next Generation in the indication Primary Immunodeficiency Disease (PID), a novel development of our polyvalent immunoglobulin G
|
| 2017 |
- Sale of US-Therapy business of Biotest Pharmaceuticals Corp. to ADMA Biologics with at the same time intensified cooperation with ADMA
- Start of European clinical phase III study in the indication Primary Immune Thrombocytopenia (ITP) of IgG Next Generation, a novel development of our polyvalent immunoglobulin G
- Chinese strategic investor Creat Group makes voluntary public takeover offer for the shares of Biotest AG
- Biotest AG shareholders accept voluntary public tender offer by Creat Group
- Takeover of Czech plasma collection company Cara Plasma s.r.o.
- Biotest opens four plasma collection centres in Europe
|
| 2018 |
- Creat takeover of Biotest after fulfilment of all conditions, amongst others the sale of the US-subsidiaries to Grifols SA
- Start of European clinical phase III study in the indication acquired fibrinogen deficiency of fibrinogen concentrate BT524, a novel high-purity fibrinogen with a defined concentration, high level of viral safety and good solubility
|
| 2019 |
- Biotest opens three plasma collection centres in Europe
- Phase III study for IgG Next Generation in Primary Immune Thrombocytopenia (ITP) successfully completed
|
| 2020 |
- Successful entry into the world's largest market for Human Albumin in China
- Phase III study for IgG Next Generation in Primary Immunodeficiency Disease (PID) successfully completed
- Biotest is one of the first plasma protein manufacturers to provide digital package leaflets for all products
COVID-19 activities
- Biotest participates in cross-industry development of a therapy for the treatment of COVID-19
- Biotest starts Phase II study with trimodulin in Covid-19 patients on mechanical ventilation with severe course
|
| 2021 |
- Biotest opens five plasma collection centres in Europe
- Grifols S.A. to make a voluntary public takeover offer for the shares of Biotest AG
- Biotest receives approval for its immunoglobulin Intratect in France
- Biotest treats first CMV-positive pregnant woman in Phase III clinical trial to prevent transmission of CMV infection to the unborn child
|
| 2022 |
- Biotest opens seven plasma collection centres in Europe
- Acquisition of the majority of voting rights in Biotest by Grifols S.A. after fulfilment of all offer conditions
- Biotest receives approval for new intravenous immunoglobulin Yimmugo (IgG Next Generation)
|
| 2023 |
- Grifols and Biotest join forces in core markets to strengthen their joint position. In this context, Biotest sells five distribution companies in Spain, Italy, UK, France and Brazil to Grifols
- Biotest opens two plasma collection centres in Europe
|
| 2024 |
- Clinical phase III study with fibrinogen concentrate successfully completed
- US approval for innovative immunoglobulin Yimmugo (IgG Next Generation) granted by FDA
- Strategic agreement with Kedrion Biopharma for distribution of Yimmugo in the USA signed
- Biotest opens four plasma collection centers in Europe
|
